Literature DB >> 10915098

Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds.

M S Dworkin1, D L Hanson, J E Kaplan, J L Jones, J W Ward.   

Abstract

To determine incidence and risk for preventable opportunistic infections (Pneumocystis carinii pneumonia [PCP] and disseminated Mycobacterium avium-complex [MAC] infection) in persons whose CD4(+) T lymphocyte counts had increased by >/=100 cells/microL to exceed the threshold of risk and in persons whose CD4(+) counts had never dropped below the threshold of risk, we analyzed data collected during the period 1990-1998 in the Adult/Adolescent Spectrum of HIV (Human Immunodeficiency Virus) Disease Project. Using a counting-process formulation of the Cox model, we analyzed observation time in these 2 groups for persons who were prescribed antiretroviral therapy but not prophylaxis. The incidences of the infections were low for patients whose CD4(+) count rose above the threshold of risk (PCP, 0.6 cases per 100 person-years [PY]; MAC, 1. 0 cases per 100 PY) and not higher than in persons whose CD4(+) counts had not decreased below these thresholds, which suggests that discontinuation of primary prophylaxis for opportunistic infections may be considered for some patients.

Entities:  

Mesh:

Year:  2000        PMID: 10915098     DOI: 10.1086/315734

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.

Authors: 
Journal:  Infect Dis Obstet Gynecol       Date:  2002

2.  A two-stage sampling method for clinical surveillance of individuals in care for HIV infection in the United States.

Authors:  Patrick S Sullivan; John M Karon; Faye E Malitz; Stephanie Broyles; Eve D Mokotoff; Susan E Buskin; Patricia L Fleming
Journal:  Public Health Rep       Date:  2005 May-Jun       Impact factor: 2.792

3.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

4.  Human immunodeficiency virus-infected patients with prior Pneumocystis pneumonia exhibit increased serologic reactivity to several major surface glycoprotein clones.

Authors:  K R Daly; J V Koch; N J Shire; L Levin; P D Walzer
Journal:  Clin Vaccine Immunol       Date:  2006-10

5.  Effect of Macrolide Prophylactic Therapy on AIDS-Defining Conditions and HIV-Associated Mortality.

Authors:  Mark Kristoffer U Pasayan; Mary Lorraine S Mationg; David Boettiger; Wilson Lam; Fujie Zhang; Stephane Wen-Wei Ku; Tuti Parwati Merati; Romanee Chaiwarith; Do Duy Cuong; Evy Yunihastuti; Sasisopin Kiertiburanakul; Nguyen Van Kinh; Anchalee Avihingsanon; Ly Penh Sun; Adeeba Kamarulzaman; Pacharee Kantipong; Nagalingeswaran Kumarasamy; Sanjay Pujari; Benedict Lim Heng Sim; Oon Tek Ng; Jun Yong Choi; Junko Tanuma; Jeremy Ross; Rossana A Ditangco
Journal:  J Acquir Immune Defic Syndr       Date:  2019-04-01       Impact factor: 3.731

6.  Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy.

Authors:  Chien-Yu Cheng; Mao-Yuan Chen; Szu-Min Hsieh; Wang-Huei Sheng; Hsin-Yun Sun; Yi-Chun Lo; Wen-Chun Liu; Chien-Ching Hung
Journal:  BMC Infect Dis       Date:  2010-05-21       Impact factor: 3.090

7.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke
Journal:  MMWR Recomm Rep       Date:  2009-09-04

8.  Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens.

Authors:  K Daly; J Koch; N Respaldiza; C de la Horra; M A Montes-Cano; F J Medrano; J M Varela; E J Calderon; P D Walzer
Journal:  Clin Microbiol Infect       Date:  2009-03-21       Impact factor: 8.067

9.  Management of Opportunistic Infection Prophylaxis in the Highly Active Antiretroviral Therapy Era.

Authors:  Hansjakob Furrer
Journal:  Curr Infect Dis Rep       Date:  2002-04       Impact factor: 3.663

Review 10.  Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic review.

Authors:  Cecilia T Costiniuk; Dean A Fergusson; Steve Doucette; Jonathan B Angel
Journal:  PLoS One       Date:  2011-12-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.